OrbiMed’s Adaptimmune Therapeutics ADAP Stock Holding History

OrbiMed’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,525,654	Closed	-$6.87M	–	136
2020 Q1	$6.87M	Buy	2,525,654 +1,174,999	+87%	+$3.9M	0.12%	95
2019 Q4	$1.62M	Hold	1,350,655	–	–	0.02%	122
2019 Q3	$2.04M	Hold	1,350,655	–	–	0.04%	107
2019 Q2	$5.43M	Hold	1,350,655	–	–	0.08%	109
2019 Q1	$5.81M	Hold	1,350,655	–	–	0.09%	104
2018 Q4	$7.77M	Buy	1,350,655 +684,062	+103%	+$5.05M	0.14%	92
2018 Q3	$9.04M	Hold	666,593	–	–	0.11%	113
2018 Q2	$7.91M	Sell	666,593 -200,000	-23%	-$2.49M	0.09%	118
2018 Q1	$9.73M	Sell	866,593 -1,048,067	-55%	-$9.17M	0.12%	105
2017 Q4	$12.8M	Hold	1,914,660	–	–	0.16%	97
2017 Q3	$15.7M	Hold	1,914,660	–	–	0.15%	93
2017 Q2	$8.6M	Hold	1,914,660	–	–	0.09%	101
2017 Q1	$10.6M	Buy	1,914,660 +1,190,476	+164%	+$5.21M	0.12%	95
2016 Q4	$2.93M	Hold	724,184	–	–	0.04%	117
2016 Q3	$5.11M	Hold	724,184	–	–	0.06%	116
2016 Q2	$5.9M	Buy	724,184 +285,400	+65%	+$2.69M	0.06%	110
2016 Q1	$3.57M	Hold	438,784	–	–	0.04%	122
2015 Q4	$5.29M	Buy	438,784 +262,314	+149%	+$2.57M	0.05%	108
2015 Q3	$2.11M	Sell	176,470 -4,234,716	-96%	-$59.8M	0.02%	123
2015 Q2	$80.9M	Buy	+4,411,186	New	+$75.7M	0.68%	45

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed's ADAP Position: Q2 2020 in Review

OrbiMed sold out of Adaptimmune Therapeutics (ADAP) in Q2 2020, closing a stake of 2,525,654 shares — an estimated $6.87M sold.

OrbiMed first reported a position in ADAP in Q2 2015 and held it in 20 quarters. The position peaked at $80.9M in Q2 2015. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2020.

OrbiMed reported no remaining Adaptimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 2,525,654 Adaptimmune Therapeutics shares in Q2 2020, an estimated $6.87M.
OrbiMed first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 20 quarters.
OrbiMed's Adaptimmune Therapeutics position peaked at $80.9M in Q2 2015.
77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.